Fig 2.

Systemic delivery of TGX221 suppresses xenograft tumor growth derived from prostate cancer cells in nude mice. Xenografts were established from prostate cancer LAPC-4 (A), LNCaP (B), 22RV1 (C) and C4-2 (D) cells. Once xenograft tumors were palpable, animals were randomized into three groups (n = 8) and treated with intravenous injection of the PPG solution (solvent control), TGX221-BL05 dissolved in PPG (naked TGX221) or nanomicellar TGX221-BL05 (nano-TGX221). Drugs were used at a dose of 100 mg/Kg body weight in 200 μl volume via tail vein twice a week for 3 weeks. Tumor sizes were monitored at each treatment and presented as a percentage value at the measurement compared to the size on the first day of treatment. Data were presented as the Mean and error bars indicate the SEM. The asterisk and pone signs indicate significant differences compared to the control group (ANOVA analysis, * P < 0.01, # P < 0.05).